CLINIMACS CD34 REAGENT N/A 171-01

MAUDE Adverse Event Report

MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed from a company representative report with the FDA on 2016-05-05 for CLINIMACS CD34 REAGENT N/A 171-01 manufactured by Miltenyi Biotec Gmbh.

Event Text Entries

[44564823] Miltenyi biotec (b)(4) has handed over an investigation questionnaire to the customer to obtain more details about the complained clinimacs? Separation. Moreover, flow cytometry data has been requested. The customer sent in a filled investigation questionnaire and a flow cytometry analysis sheet from the target fraction. Based on the given information following statement can be made: the source product for the selection procedura was a fresh, mobilized leukapheresis product, containing 35xl0e9 tnc (total nucleated cells) and 364. 8xl0e6 cd34 +-cells (= 1. 04% cd34+). The separation was performed with one vial of clinimacs? Cd34 reagent, and the respective clinimacs? Tubing set. The reagent was used within the specification using the enrichment program cd34 selection 1. The process code does not indicate any malfunction of the clinimacs? Plus instrument. Igg was added prior labeling for blocking of unspecific binding sites. Only 12. 1x106 out the initial 365x106 cd34-t- cells were found in the target cell bag. The resulting target cell recovery is therefore 3. 3%. No flow cytometry data available for negative fraction and/or initial cell product. The flow analysis data sheet from the target cell fraction does not indicate any discrepancies in the gating. The purity for cd34+ stem cells was 88. 4%. Small aggregates were observed in the original fraction. Based on the data provided by the customer it is impossible to make any assessment regarding the possible root cause. The reagent was used within the specification. No major deviations from the recommended protocol have been identified. No malfunction of the clinimacs? Plus instrument has been identified by the process code. But, it could not be ruled out whether low recovery was caused by: unfavorable composition of the initial cell product (cell aggregates were observed).
Patient Sequence No: 1, Text Type: N, H10


[44564824] The customer complained that the recovery of cd34+- cells was low (3. 3%) for a clinimacs? Separation procedura.
Patient Sequence No: 1, Text Type: D, B5


MAUDE Entry Details

Report Number3005290010-2016-00066
MDR Report Key5635406
Report SourceCOMPANY REPRESENTATIVE
Date Received2016-05-05
Date of Report2016-05-04
Date of Event2016-03-24
Date Mfgr Received2016-04-06
Device Manufacturer Date2015-12-21
Date Added to Maude2016-05-05
Event Key0
Report Source CodeManufacturer report
Manufacturer LinkY
Number of Patients in Event0
Adverse Event Flag3
Product Problem Flag3
Reprocessed and Reused Flag3
Reporter OccupationOTHER HEALTH CARE PROFESSIONAL
Health Professional3
Initial Report to FDA3
Report to FDA3
Event Location3
Manufacturer ContactMS NANCY JOHANSEN
Manufacturer Street85 HAMILTON ST
Manufacturer CityCAMBRIDGE MA 02139
Manufacturer CountryUS
Manufacturer Postal02139
Manufacturer Phone6172180062
Manufacturer G1MILTENYI BIOTEC GMBH
Manufacturer StreetFRIEDRICH-EBERT-STRASSE 68
Manufacturer CityBERGISCH GLADBACH, 51429
Manufacturer CountryGM
Manufacturer Postal Code51429
Single Use3
Remedial ActionNO
Previous Use Code3
Event Type3
Type of Report3

Device Details

Brand NameCLINIMACS CD34 REAGENT
Generic NameCLINIMACS CD34 REAGENT
Product CodeOVG
Date Received2016-05-05
Model NumberN/A
Catalog Number171-01
Lot Number6151218004
Device Expiration Date2016-05-18
OperatorHEALTH PROFESSIONAL
Device AvailabilityN
Device Eval'ed by MfgrR
Device Sequence No1
Device Event Key0
ManufacturerMILTENYI BIOTEC GMBH
Manufacturer AddressFRIEDRICH-EBERT-STRASSE 68 BERGISCH GLADBACH, 51429 GM 51429


Patients

Patient NumberTreatmentOutcomeDate
10 2016-05-05

© 2025 FDA.report
This site is not affiliated with or endorsed by the FDA.